Farmas USA

Me acaba de llegar, nuevas coverturas .

Healthcare ratings roundup - new coverage

Jun 10 2016, 07:19 ET | By:  Douglas W. House, SA News Editor 

Boston Scientific (NYSE: BSX) initiated with Buy rating and $26 (13% upside) price target by Guggenheim Securities.

Zimmer Biomet Holdings (NYSE: ZBH) initiated with Neutral rating and $140 (18% upside) price target by Guggenheim Securities.

Edwards Lifesciences (NYSE: EW) initiated with Neutral rating and $120 (18% upside) price target by Guggenheim Securities.

Oncobiologics (Pending: ONS) initiated with Buy rating and $15 (218% upside) price target by Cantor Fitzgerald.

Walgreens Boots Alliance (NASDAQ: WBA) reinstated with Buy rating and $95 (20% upside) price target by Bank of America.

Goldman Sachs initiates coverage of specialty pharma with a Neutral rating:  Buy: Jazz Pharma (NASDAQ: JAZZ) - $196 (26% upside) price target, Horizon Pharma (NASDAQ: HZNP) - $24 (30% upside) price target;  Neutral: Endo International (NASDAQ: ENDP) - $20 (11% upside) price target, Mallinckrodt (NYSE: MNK) - $73 (17% upside) price target, Momenta Pharmaceuticals (NASDAQ: MNTA) - $14 (19% upside) price target; Concordia Healthcare (NASDAQ: CXRX) - $32 (31% upside) price target;  Sell: Impax Laboratories (NASDAQ: IPXL) - $33 (2% downside risk) price target.

Biocept (NASDAQ: BIOC) initiated with Buy rating and $1.20 (71% upside) price target by Roth Capital.

Seres Therapeutics (NASDAQ: MCRB) initiated with Outperform rating and $40 (22% upside) price target by Cowen & Company.

Omeros (NASDAQ: OMER) initiated with Buy rating and $21 (94% upside) price target by Cantor Fitzgerald.

Glaukos (NYSE: GKOS) initiated with Buy rating and $35 (30% upside) price target by Cantor Fitzgerald.

Shire plc (NASDAQ: SHPG) initiated with Overweight rating and GBX5,600 (34% upside) price target by Morgan Stanley.

ACHN,
No se framus, probablemente hoy se de la vuelta pero las news de EHA de esta mañana deberían por lo menos servir de gap up a apertura. veremos a ver...

ojala te rompa esa bajista :)

ACHN

ACHN
a ver! desde luego, el sector no acompaña nada hoy! he puesto orden de venta de apertura de un % pequeño de mis acciones, por si hubiera sorpresa en apertura, no vaya a ser que necesite cash para mas NVAX ;)

NVAX

Pues ahí dice que Stan mostró una diapositiva con la fase III completada y que partner en los próximos 3-6 meses; el quid de la cuestión es cuál.

por lo que dijeron en la CC del report financiero ... una Big Pharma. No nos van a salir con una "kowa pharmaceuticals" como Amarin.

NVAX

joer que dip las NVAX, para haber pescado buenos cromos .. y por el recovery que lleva ( a tapar el gap de apertura en 6,61 )  para haber hecho un buen mete-saca.

Me perdi la apertura, cachis

NVAX

Nvax
No la veo cómoda en rojo !vamos!